Arrivo

Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

Retrieved on: 
Tuesday, April 16, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Cyclothymia, Major depressive disorder, Diabetes, Depression, Literature, Obesity, DNA, DSM-IV codes, Patient, MADRS, Gene expression, DNA repair, SIRT6, Biomarker, Ageing, Clinical trial, Arrivo, MDD, Pharmaceutical industry

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

Key Points: 
  • Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
  • This registration-quality Phase 2b study will enroll 450 subjects with MDD and evaluate the effectiveness of SP-624, a SIRT6 activator and novel mechanism of action, compared to placebo in treating adults with Major Depressive Disorder.
  • The SP-624-202 study will assess the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) as its primary endpoint.
  • The MADRS is a 10-item depression rating scale commonly used to assess the severity of depression in clinical trials.

Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board

Retrieved on: 
Monday, March 18, 2024
Depression, Psychosis, Neurology, ADHD, Entrepreneurship, Biomarker, RNA, Harvard Business School, Fellow, University, Doctor of Philosophy, Senior, Medicine, MBA, Genomics, DSM-IV codes, Fortune 500, SAB, Arrivo, Eli Lilly and Company, Psychiatry

ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB).

Key Points: 
  • ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB).
  • Dr. Ackermann brings significant expertise in biopharmaceutical industry including antidepressant drug development to Circular Genomics.
  • Circular Genomics is at the forefront of introducing precision medicine into mental health care.
  • Since 2015, he has been serving as Co-Founder, Board Member, and Chief Business Officer at Arrivo BioVentures LLC.

ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

Retrieved on: 
Wednesday, November 29, 2023
Mental Health, Health, General Health, Clinical Trials, Research, Science, Biotechnology, DNA, DSM-IV codes, Grammatical mood, Patient, Pelvic floor dysfunction, Male, Metabolism, FDA, Fat necrosis, Gene expression, Series, Acute pancreatitis, DNA repair, SIRT6, Death, Pancreatitis, Female, MDD, Pharmaceutical industry, Arrivo

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.

Key Points: 
  • Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.
  • “We are extremely grateful to our investors who continue to believe in our team and our promising pipeline,” said Steve Butts, CEO of Arrivo.
  • Orlando Health Ventures led the Series B financing with additional investment from Solas BioVentures Emerging Healthcare Fund, L.P., Rex Health Ventures and several private investors.
  • “Oversubscribed capital fundraising is rare in today’s market, and today’s Series B closing is a testament to the strong data behind both pipeline treatments, SP-624 and RABI-767, which have the potential to change millions of patients’ lives.”

Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder

Retrieved on: 
Thursday, May 26, 2022
Mental Health, Health, Genetics, Pharmaceutical, Clinical Trials, DNA, Lists of diseases, MADRS, Metabolism, Patient, DNA repair, Gene expression, Clinical trial, Trial of the century, Psoriasis, Partnership, Safety, Research Triangle Park, Drug development, Triangle Park (Quezon City), Acute pancreatitis, Arrivo, Prefrontal cortex, LLC, Hippocampus, Pharmaceutical industry

Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder.

Key Points: 
  • Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder.
  • The study is a multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of SP-624 in the treatment of adults with major depressive disorder.
  • The trial is being conducted across 39 clinical trial sites in the United States with a total of 319 patients enrolled.
  • The primary endpoint is the change from baseline to Week 4 in the Montgomery Asberg Depression Rating Scale (MADRS) total score.

Arrivo BioVentures Emerges from Stealth Mode with a Robust Pipeline and Promising Data

Retrieved on: 
Monday, December 13, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Research Triangle Park, Prefrontal cortex, Hippocampus, Arrivo, History, Acute pancreatitis, Doctor of Philosophy, Triangle Park (Quezon City), Nature, LLC, Serum, Safety, Patient, Disease, Drug development, Lists of diseases, Partnership, Depression, Psoriasis, Pharmaceutical industry

The company has built a robust pipeline of products that have the potential to be first-in-class or best-in-class across a number of therapeutic areas.

Key Points: 
  • The company has built a robust pipeline of products that have the potential to be first-in-class or best-in-class across a number of therapeutic areas.
  • Arrivo is disclosing promising results from a Phase 1 study with DLX-2323, its single-chain variable fragment inhibitor of IL-1.
  • Arrivo continues to be excited about the future for DLX-2323 and its potential across a number of diseases and disorders.
  • Arrivo is founded and led by a team that has built and sold four companies in the last 15 years.

Local Logic Strengthens US Presence with Leadership Appointment

Retrieved on: 
Thursday, December 16, 2021
Arrivo, City, Growth, Industry, AI, CEO, Travel, Property technology, VP, Aviation, Toys "R" Us Canada, Commercial finance advisor, Partnership, Technology, Logic, SmartCentres, Financial services, Finance, Mulholland, Analysis

Additionally, Mulholland will build a finance, planning, and analysis team and work in partnership with Local Logic's executive and accounting teams to optimize the company's overall performance.

Key Points: 
  • Additionally, Mulholland will build a finance, planning, and analysis team and work in partnership with Local Logic's executive and accounting teams to optimize the company's overall performance.
  • Before joining Local Logic, Mulholland served as the Finance Advisor for sustainable aviation startup Craft Aerospace and VP of Finance and Operations at energy and climate optimization platform EntoLabs.ai.
  • His deep understanding of finance, technology, and startups will also support Local Logic as the software company scales and pursues its upcoming fundraise.
  • To learn more about Mulholland and Local Logic, please visit: http://www.locallogic.co .

University of San Francisco's School of Management to Host "Autonomous Vehicles and the City" Symposium on October 15

Retrieved on: 
Friday, October 12, 2018
California, Lyft, Sustainable transport, University of San Francisco, San Francisco, Proterra, Inc., Arrivo, USF

SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ --The School of Management at the University of San Francisco (USF) will host the "Autonomous Vehicles and the City" symposium on Monday, October 15 from 8:00 a.m. to 6:00 p.m. at the McLaren Conference Center on the USF campus.

Key Points: 
  • SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ --The School of Management at the University of San Francisco (USF) will host the "Autonomous Vehicles and the City" symposium on Monday, October 15 from 8:00 a.m. to 6:00 p.m. at the McLaren Conference Center on the USF campus.
  • The day-long symposium will bring together 200 national leaders in business, policy, and academia to discuss how we can innovate cities in the new mobility future focusing on economic growth, energy and the environment, land use and design, social justice, policy and management.
  • The event will include expert panel discussions with representatives from companies including Arup, AC Transit, Arrivo-Loop, BMW, Brigade, Cruise, Fehr & Peers, Ford, Lime, Lyft, MayMobility, Populus, Proterra, Remix, Xapix and more.
  • The outcome of the event will conclude with two workshops on design and management with a focus on rethinking how we design and manage streets to respond to and inform new transportation innovations.

Is Your Region Ready for a Next Generation Hyperloop? Arrivo Announces US $1 Billion of Project Financing.

Retrieved on: 
Thursday, July 19, 2018
Hyperloop, Arrivo, Hyperloop One, Project management, Science and technology in the United States, Economy of the United States, Transport

"Arrivo provides a unique solution for regional mobility and a great complement to high speed rail and airports.

Key Points: 
  • "Arrivo provides a unique solution for regional mobility and a great complement to high speed rail and airports.
  • "The demand for urban mobility is increasing, and technologies such as autonomous vehicles will only increase demand," notes Arrivo CEO Brogan BamBrogan.
  • CNTIC is a large scale state-owned enterprise with main businesses in technology trade, project contracting and project management integrated service.
  • CNTIC has strong ability in the fields of marketing, business integration, project management, project engineering, investing and financing.